Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women : Results from a Randomized, Double-Blind Placebo-Controlled Study. / Halkjær, Sofie Ingdam; de Knegt, Victoria Elizabeth; Lo, Bobby; Nilas, Lisbeth; Cortes, Dina; Pedersen, Anders Elm; Mirsepasi-Lauridsen, Hengameh Chloé; Andersen, Lee O'Brien; Nielsen, Henrik Vedel; Stensvold, Christen Rune; Johannesen, Thor Bech; Kallemose, Thomas; Krogfelt, Karen Angeliki; Petersen, Andreas Munk.
I: Current Developments in Nutrition, Bind 4, Nr. 7, nzaa095, 2020.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women
T2 - Results from a Randomized, Double-Blind Placebo-Controlled Study
AU - Halkjær, Sofie Ingdam
AU - de Knegt, Victoria Elizabeth
AU - Lo, Bobby
AU - Nilas, Lisbeth
AU - Cortes, Dina
AU - Pedersen, Anders Elm
AU - Mirsepasi-Lauridsen, Hengameh Chloé
AU - Andersen, Lee O'Brien
AU - Nielsen, Henrik Vedel
AU - Stensvold, Christen Rune
AU - Johannesen, Thor Bech
AU - Kallemose, Thomas
AU - Krogfelt, Karen Angeliki
AU - Petersen, Andreas Munk
N1 - Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.
PY - 2020
Y1 - 2020
N2 - Background: Maternal obesity is associated with adverse pregnancy outcomes. Probiotic supplementation during pregnancy may have positive effects on blood glucose, gestational weight gain (GWG), and the risk of gestational diabetes mellitus [GDM and glycated hemoglobin (HbA1c)].Objectives: This feasibility study involved a daily probiotic intervention in obese pregnant women from the early second trimester until delivery. The primary aim was to investigate the effect on GWG and maternal glucose homeostasis (GDM and HbA1c). Secondary aims were the effect on infant birth weight, maternal gut microbiota, and other pregnancy outcomes.Methods: We carried out a randomized double-blinded placebo-controlled study in 50 obese pregnant women. Participants were randomly allocated (1:1) to multistrain probiotic (4 capsules of Vivomixx®; total of 450 billion CFU/d) or placebo at 14-20 weeks of gestation until delivery. Participants were followed with 2 predelivery visits at gestational week 27-30 and 36-37 and with 1 postdelivery visit. All visits included blood and fecal sampling. An oral-glucose-tolerance test was performed at inclusion and gestational week 27-30.Results: Forty-nine participants completed the study. Thirty-eight participants took >80% of the capsules (n = 21), placebo (n = 17). There was no significant difference in GWG, GDM, HbA1c concentrations, and infant birth weight between groups. Fecal microbiota analyses showed an overall increase in α-diversity over time in the probiotic group only (P = 0.016).Conclusions: Administration of probiotics during pregnancy is feasible in obese women and the women were willing to participate in additional study visits and collection of fecal samples during pregnancy. Multistrain probiotic can modulate the gut microbiota in obese women during pregnancy. A larger study population is needed to uncover pregnancy effects after probiotic supplementation. This trial was registered at clincaltrials.gov as NCT02508844.
AB - Background: Maternal obesity is associated with adverse pregnancy outcomes. Probiotic supplementation during pregnancy may have positive effects on blood glucose, gestational weight gain (GWG), and the risk of gestational diabetes mellitus [GDM and glycated hemoglobin (HbA1c)].Objectives: This feasibility study involved a daily probiotic intervention in obese pregnant women from the early second trimester until delivery. The primary aim was to investigate the effect on GWG and maternal glucose homeostasis (GDM and HbA1c). Secondary aims were the effect on infant birth weight, maternal gut microbiota, and other pregnancy outcomes.Methods: We carried out a randomized double-blinded placebo-controlled study in 50 obese pregnant women. Participants were randomly allocated (1:1) to multistrain probiotic (4 capsules of Vivomixx®; total of 450 billion CFU/d) or placebo at 14-20 weeks of gestation until delivery. Participants were followed with 2 predelivery visits at gestational week 27-30 and 36-37 and with 1 postdelivery visit. All visits included blood and fecal sampling. An oral-glucose-tolerance test was performed at inclusion and gestational week 27-30.Results: Forty-nine participants completed the study. Thirty-eight participants took >80% of the capsules (n = 21), placebo (n = 17). There was no significant difference in GWG, GDM, HbA1c concentrations, and infant birth weight between groups. Fecal microbiota analyses showed an overall increase in α-diversity over time in the probiotic group only (P = 0.016).Conclusions: Administration of probiotics during pregnancy is feasible in obese women and the women were willing to participate in additional study visits and collection of fecal samples during pregnancy. Multistrain probiotic can modulate the gut microbiota in obese women during pregnancy. A larger study population is needed to uncover pregnancy effects after probiotic supplementation. This trial was registered at clincaltrials.gov as NCT02508844.
U2 - 10.1093/cdn/nzaa095
DO - 10.1093/cdn/nzaa095
M3 - Journal article
C2 - 32617453
VL - 4
JO - Current Developments in Nutrition
JF - Current Developments in Nutrition
SN - 2475-2991
IS - 7
M1 - nzaa095
ER -
ID: 244915160